Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Granahan Investment Management LLC

Granahan Investment Management LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 2.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 154,418 shares of the company’s stock after acquiring an additional 3,840 shares during the quarter. Granahan Investment Management LLC owned approximately 0.12% of Apellis Pharmaceuticals worth $4,927,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of APLS. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after buying an additional 758 shares during the last quarter. Signaturefd LLC increased its stake in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the period. US Bancorp DE increased its stake in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after acquiring an additional 1,327 shares during the period. Covestor Ltd raised its holdings in Apellis Pharmaceuticals by 1,819.2% during the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after purchasing an additional 3,784 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Apellis Pharmaceuticals by 89.0% in the 4th quarter. Russell Investments Group Ltd. now owns 6,107 shares of the company’s stock valued at $195,000 after purchasing an additional 2,876 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Raymond James downgraded Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their target price for the stock from $75.00 to $52.00 in a research note on Friday. Bank of America downgraded Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $41.00 to $23.00 in a report on Friday. Royal Bank of Canada decreased their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $41.37.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 6,115 shares of company stock worth $154,684 in the last three months. Company insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Trading Down 2.9 %

Shares of APLS opened at $17.30 on Friday. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $43.99. The stock has a fifty day moving average of $21.15 and a two-hundred day moving average of $27.05. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a market capitalization of $2.17 billion, a PE ratio of -8.52 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) earnings per share. As a group, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).